Facebook Twitter 新浪微博 腾讯微博 Wednesday 3 June 2015
Search
Archive
English
English>>Business

Online prescription drug sales to be allowed

(Shanghai Daily)    08:38, January 12, 2015
Email|Print

China will allow online sales of prescription drugs as early as this month, a policy that will open up an over 1 trillion yuan (US$161 billion) market to online pharmacy operators like Alibaba Group Holding Ltd and Wal-Mart Stores Inc.

The China Food and Drug Administration (CFDA) is finalizing which prescription medicines to approve for sale, a senior health care policy adviser said.

The policy would help reform a fragmented and opaque market controlled by state-run distributors and hospitals, brought into the spotlight last year by a bribery case which saw GlaxoSmithKline Plc fined nearly US$500 million.

“The policy will be released in January or February and the CFDA is actively working on it,” said the adviser, who was not authorized to speak with media on the matter and so declined to be identified.

Hospitals currently account for around 70 percent of drugs sold to consumers. Among retailers, online pharmacies are restricted to selling over-the-counter medicines and health care products such as cough remedies and vitamin tablets.

The new policy could eventually allow online retail pharmacies such as Alibaba Health Information Technology Ltd and the pharmacy platform of JD.com Inc to wrest sales from hospitals.

Frank Zhao, chief financial officer at China Jo-Jo Drugstores Inc, said the CFDA was checking the list of prescription drugs for sale online. “It may be a couple of days or weeks before the final list,” he said.

Pharmacies with an online presence, such as US-listed Jo-Jo Drugstores and China Nepstar Chain Drugstore Ltd, as well as general online retailers also stand to benefit. Alibaba and JD.com already have licenses to sell over-the-counter drugs online, as does Wal-Mart.

Initially, online prescription drug sales are likely to be business-to-business before spreading to retailers. The potential size of the B2B drug market ranges from 300 billion yuan to as much as 800 billion yuan, said Deutsche Bank.

At risk could be offline middlemen such as Sinopharm Group Co, Shanghai Pharmaceuticals and China Medical Systems Holdings Ltd.

It will take considerable time for companies and consumers to get used to the new model, said Jo-Jo Drugstores’ Zhao. In the US, around a third of drugs are sold online compared with almost zero currently in China, Zhao said.

Drugs sold online may be up to 10 percent cheaper than those sold through traditional channels, analysts say.

“The government has a common theme — to improve quality of care for the masses and at the same time contain costs,” said Andrew Chen, head of PwC’s China Consulting Healthcare practice. “So, the e-pharmacy side is definitely going to be a trend.”

(For the latest China news, Please follow People's Daily on Twitter and Facebook)(Editor:Ma Xiaochun,Liang Jun)

Add your comment

Related reading

We Recommend

Most Viewed

Day|Week

Key Words